Axa S.A. Insmed Inc Transaction History

Axa S.A.

$33.6 Billion
Q2 2025

A detailed history of Axa S.A. transactions in Insmed Inc stock. As of the latest transaction made, Axa S.A. holds 226,603 shares of INSM stock, worth $36.6 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

226,603

Previous 203,857 11.16%

Holding current value

$36.6 Million

Previous $15.6 Million 46.64%

% of portfolio

0.07%

Previous 0.05%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$64.81 - $105.9 $1.47 Million - $2.41 Million	22,746 Added 11.16%	226,603 $22.8 Million
Q1 2025 May 15, 2025	SELL	$65.25 - $83.83 $1.5 Million - $1.93 Million	-22,964 Reduced 10.12%	203,857 $15.6 Million
Q4 2024 Feb 14, 2025	SELL	$66.29 - $76.63 $23,864 - $27,586	-360 Reduced 0.16%	226,821 $15.7 Million
Q3 2024 Nov 14, 2024	BUY	$62.0 - $79.01 $3,906 - $4,977	63 Added 0.03%	227,181 $16.6 Million
Q2 2024 Feb 25, 2025	BUY	$22.0 - $69.71 $6,534 - $20,703	297 Added 0.13%	227,118 $15.2 Million
Q2 2024 Aug 14, 2024	SELL	$22.0 - $69.71 $1.35 Million - $4.29 Million	-61,481 Reduced 21.3%	227,118 $15.2 Million
Q1 2024 May 15, 2024	SELL	$25.72 - $29.94 $1.63 Million - $1.9 Million	-63,447 Reduced 18.02%	288,599 $7.83 Million
Q4 2023 Jul 16, 2024	BUY	$23.42 - $31.74 $1.49 Million - $2.01 Million	63,447 Added 21.98%	352,046 $10.9 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $199,421 - $270,266	-8,515 Reduced 2.36%	352,046 $10.9 Million
Q3 2023 Nov 14, 2023	SELL	$19.86 - $26.93 $9.72 Million - $13.2 Million	-489,553 Reduced 57.59%	360,561 $9.1 Million
Q2 2023 Aug 14, 2023	BUY	$16.44 - $21.1 $1.4 Million - $1.8 Million	85,328 Added 11.16%	850,114 $17.9 Million
Q1 2023 May 15, 2023	SELL	$16.26 - $21.73 $55,479 - $74,142	-3,412 Reduced 0.44%	764,786 $13 Million
Q4 2022 Feb 14, 2023	SELL	$16.98 - $23.15 $16,215 - $22,108	-955 Reduced 0.12%	768,198 $15.3 Million
Q3 2022 Feb 14, 2023	SELL	$20.88 - $28.21 $360,180 - $486,622	-17,250 Reduced 2.19%	769,153 $16.6 Million
Q3 2022 Nov 14, 2022	SELL	$20.88 - $28.21 $360,180 - $486,622	-17,250 Reduced 2.19%	769,153 $16.6 Million
Q2 2022 Feb 14, 2023	SELL	$17.07 - $25.71 $145,555 - $219,229	-8,527 Reduced 1.07%	786,403 $15.5 Million
Q2 2022 Aug 15, 2022	SELL	$17.07 - $25.71 $145,555 - $219,229	-8,527 Reduced 1.07%	786,403 $15.5 Million
Q1 2022 Feb 14, 2023	BUY	$20.42 - $28.13 $526,366 - $725,107	25,777 Added 3.35%	794,930 $18.7 Million
Q1 2022 May 13, 2022	SELL	$20.42 - $28.13 $120,457 - $165,938	-5,899 Reduced 0.74%	794,930 $18.7 Million
Q4 2021 Feb 14, 2022	BUY	$25.89 - $33.45 $2.61 Million - $3.37 Million	100,629 Added 14.37%	800,829 $21.8 Million
Q3 2021 Nov 15, 2021	BUY	$22.46 - $29.47 $1.61 Million - $2.12 Million	71,772 Added 11.42%	700,200 $19.3 Million
Q2 2021 Aug 13, 2021	BUY	$24.17 - $36.01 $2.7 Million - $4.02 Million	111,683 Added 21.61%	628,428 $17.9 Million
Q1 2021 May 14, 2021	SELL	$32.28 - $44.3 $392,783 - $539,042	-12,168 Reduced 2.3%	516,745 $17.6 Million
Q4 2020 Feb 12, 2021	BUY	$31.45 - $40.54 $279,213 - $359,914	8,878 Added 1.71%	528,913 $17.6 Million
Q3 2020 Nov 13, 2020	SELL	$26.0 - $34.5 $2.67 Million - $3.54 Million	-102,635 Reduced 16.48%	520,035 $16.7 Million
Q2 2020 Aug 14, 2020	BUY	$14.11 - $29.42 $1.06 Million - $2.2 Million	74,925 Added 13.68%	622,670 $17.1 Million
Q1 2020 May 15, 2020	BUY	$13.63 - $33.98 $5.14 Million - $12.8 Million	376,837 Added 220.49%	547,745 $8.78 Million
Q4 2019 Feb 18, 2020	BUY	$16.12 - $24.98 $2.76 Million - $4.27 Million	170,908 New	170,908 $4.08 Million
Q4 2017 Feb 13, 2018	SELL	$26.43 - $31.78 $1.87 Million - $2.25 Million	-70,734 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$11.61 - $31.21 $821,221 - $2.21 Million	70,734	70,734 $2.21 Million

Others Institutions Holding INSM

# of Institutions

582

Shares Held

203M

Call Options Held

2.84M

Put Options Held

3.26M

View Full List

About INSMED Inc

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $21.9B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

More about INSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account